These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. Yatsuji S; Hashimoto E; Tobari M; Taniai M; Tokushige K; Shiratori K J Gastroenterol Hepatol; 2009 Feb; 24(2):248-54. PubMed ID: 19032450 [TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Struben VM; Hespenheide EE; Caldwell SH Am J Med; 2000 Jan; 108(1):9-13. PubMed ID: 11059435 [TBL] [Abstract][Full Text] [Related]
9. The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. Younossi Z; Stepanova M; Sanyal AJ; Harrison SA; Ratziu V; Abdelmalek MF; Diehl AM; Caldwell S; Shiffman ML; Schall RA; McColgan B; Subramanian GM; Myers RP; Muir A; Afdhal NH; Bosch J; Goodman Z J Hepatol; 2018 Dec; 69(6):1365-1370. PubMed ID: 30144554 [TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Yalamanchili K; Saadeh S; Klintmalm GB; Jennings LW; Davis GL Liver Transpl; 2010 Apr; 16(4):431-9. PubMed ID: 20373454 [TBL] [Abstract][Full Text] [Related]
11. [Two cases of patients with hepatocellular carcinoma (HCC) that developed in cryptogenic cirrhosis suggestive of nonalcoholic steatohepatitis (NASH) as background liver disease after clinical courses of 26 years]. Tsutsumi K; Nakayama H; Sakai Y; Kojima Y; Dairaku N; Ojima T; Kusano M; Ikeya S; Sugai Y; Hiwatashi N Nihon Shokakibyo Gakkai Zasshi; 2007 May; 104(5):690-7. PubMed ID: 17485950 [TBL] [Abstract][Full Text] [Related]
12. Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants. O'Leary JG; Landaverde C; Jennings L; Goldstein RM; Davis GL Clin Gastroenterol Hepatol; 2011 Aug; 9(8):700-704.e1. PubMed ID: 21570483 [TBL] [Abstract][Full Text] [Related]
13. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Contos MJ; Cales W; Sterling RK; Luketic VA; Shiffman ML; Mills AS; Fisher RA; Ham J; Sanyal AJ Liver Transpl; 2001 Apr; 7(4):363-73. PubMed ID: 11303298 [TBL] [Abstract][Full Text] [Related]
14. Is cryptogenic cirrhosis different from NASH cirrhosis? Thuluvath PJ; Kantsevoy S; Thuluvath AJ; Savva Y J Hepatol; 2018 Mar; 68(3):519-525. PubMed ID: 29162389 [TBL] [Abstract][Full Text] [Related]
15. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Salomao M; Yu WM; Brown RS; Emond JC; Lefkowitch JH Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341 [TBL] [Abstract][Full Text] [Related]
16. [Clinical characteristics of non-alcoholic steatohepatitis (NASH) patients who progressed from F3 stage fibrosis to cirrhotic NASH]. Kawanaka M; Oka T; Urata N; Kimura T; Nakamura J; Goto D; Yamato R; Nishino K; Suehiro M; Kawamoto H; Yamada G Nihon Shokakibyo Gakkai Zasshi; 2012 Dec; 109(12):2042-8. PubMed ID: 23221052 [TBL] [Abstract][Full Text] [Related]
20. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. Malik R; Chang M; Bhaskar K; Nasser I; Curry M; Schuppan D; Byrnes V; Afdhal N J Gastroenterol Hepatol; 2009 Apr; 24(4):564-8. PubMed ID: 19378390 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]